Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 15/20 | 0.44 |
| ▸ | NR1H3 | Q13133 | 14/20 | 0.44 |
| ▸ | RXRA | P19793 | 9/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | MC4R | P32245 | 1/20 | 0.37 |
| ▸ | MC5R | P33032 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30595864 | 0.85 | RIPK1 (0.53) | NR1H2NR1H3RXRARIPK1 | |
| SCHEMBL2640496 | 0.84 | NR1H2 (0.45) | NR1H2NR1H3RXRAPARP1RIPK1 | |
| SCHEMBL8223030 | 0.84 | RIPK1 (0.51) | NR1H2NR1H3RXRAMAPTNPSR1 | |
| SCHEMBL874416 | 0.84 | NR1H2 (0.49) | NR1H2NR1H3RXRAPARP1RIPK1 | |
| SCHEMBL22285173 | 0.84 | NR1H2 (0.49) | NR1H2NR1H3RXRAPARP1RIPK1 | |
| SCHEMBL4325057 | 0.84 | NR1H2 (0.49) | NR1H2NR1H3RXRAPARP1RIPK1 | |
| SCHEMBL8878226 | 0.81 | PARP1 (0.45) | NR1H2NR1H3RXRAMAPTNPSR1 | |
| SCHEMBL28040244 | 0.79 | NR1H2 (0.45) | NR1H2NR1H3RXRA | |
| SCHEMBL27757870 | 0.78 | NR1H2 (0.40) | NR1H2NR1H3RXRAPARP1 | |
| SCHEMBL3697218 | 0.78 | DPP4 (0.47) | NR1H2NR1H3PARP1MC4RMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | DRD3, CHRNA3, CHRM3 | NR1H2 1295/4885NR1H3 1017/4885RXRA 1434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.